• Axitinib: Evidence, Interpretation, and Limits

  2026-10-07

  A source-grounded overview of Axitinib (AG 013736), covering VEGF receptor biology, evidence quality, viability metrics, preclinical interpretation, and the boundaries of conclusions from in vitro and xenograft research.

• Ribociclib Succinate: CDK Inhibitor Evidence

  2026-10-07

  LEE011 succinate is a research CDK inhibitor used to study CDK4/6-linked cell cycle regulation. Product specifications support chemical characterization, while clinical evidence from degarelix-treated prostate cancer addresses a separate testosterone-bounce question and does not establish ribociclib efficacy.

• Approved Drugs and DNA Repair in CRISPR

  2026-10-06

  Macak, Kanis, and Riesenberg report a large repurposing screen that links clinically approved drugs with distinct DNA double-strand break repair outcomes in human induced pluripotent stem cells. The study identifies candidate modulators of NHEJ, MMEJ, and HDR, highlights ESR2 and AOX1 as relevant biological factors, and frames drug-induced repair bias as a potential tool for genome editing and synthetic lethality research.

• HyperScript RT SuperMix for qPCR: Evidence Context

  2026-10-05

  HyperScript RT SuperMix for qPCR is a premixed reverse-transcription solution for two-step qRT-PCR and cDNA synthesis for qPCR. Its manufacturer describes engineered thermal stability, a mixed-primer design, and compatibility with dye- and probe-based detection, while the cited URSA study provides biological context rather than direct validation of this specific reagent.

• C34 TLR4 Inhibitor: Evidence Across Models

  2026-10-05

  C34 is a selective TLR4 inhibitor for investigating inflammatory signaling across macrophage, enterocyte, intestinal, and microglial models. This evidence-focused analysis explains how C34 can serve as a pharmacological reference point while distinguishing reported findings from hypotheses and translational limitations.

• Electroporation for CRISPR Editing in Mouse Zygotes

  2026-10-04

  Hashimoto and Takemoto showed that electroporation could deliver CRISPR/Cas9-related RNA into mouse zygotes without removing the zona pellucida, addressing a throughput limitation of microinjection. Their findings support a scalable conceptual route for embryo genome engineering, while leaving important questions about locus-specific efficiency, embryo viability, and transferability to other systems.

• Nadolol (SQ-11725): Evidence and Research Context

  2026-10-03

  A source-grounded overview of Nadolol (SQ-11725) for cardiovascular and transporter-focused research, distinguishing supplier-described properties from findings in a 2025 mouse pharmacokinetic study that examined Corydalis saxicola alkaloids rather than Nadolol.

• Atorvastatin: Practical Research Workflows

  2026-10-02

  Build reproducible Atorvastatin assays across cholesterol metabolism, vascular cell biology, and ferroptosis-oriented liver cancer research. This guide combines formulation, dose-finding, phenotype validation, and troubleshooting while separating established product data from exploratory protocol recommendations.

• Laminin (925-933): Practical Assay Guide

  2026-10-01

  Laminin (925-933), SKU A1023, provides a defined Laminin B1 chain peptide for testing laminin-receptor-associated cell attachment and chemotaxis without using full-length laminin. This guide explains preparation, controls, and interpretation boundaries; it should not be treated as evidence that the peptide reproduces the complete structure or activity of native basement membrane laminin.

• N2703 and the Adipose–Neural Signaling Axis

  2026-10-01

  A translational framework for using 3-(1-methylpyrrolidin-2-yl)pyridine (N2703) to interrogate adipose–neural mechanisms, cardiac electrophysiology, and pathway-level causality without overstating an uncharacterized target profile.

• NS1–DNMT1 Control of HBoV1 Replication

  2026-09-30

  A 2024 PLOS Pathogens study identifies DNMT1-dependent DNA methylation as a regulator of human bocavirus 1 replication and RNA maturation. It further shows that viral NS1 promotes DNMT1 degradation through the ubiquitin–proteasome pathway, linking viral DNA synthesis, transcript processing, and protein expression.

• SpCas9 mRNA for Embryo Genome Engineering

  2026-09-30

  SpCas9 mRNA enables transient, guide-directed editing without requiring a DNA expression cassette, making it useful for embryo, stem-cell, and other eukaryotic workflows. Its ARCA cap, poly(A) tail, 5mCTP, ψUTP, dual NLS motifs, and HA tag support a translation-aware workflow that can be connected to chromatin and developmental assays.

• Antiepileptic Drugs and Human Aromatase (CYP19)

  2026-09-29

  The reference study systematically tested 12 antiepileptic drugs for inhibition of human aromatase, identifying lamotrigine among seven compounds that reduced CYP19 activity in a recombinant microsomal assay. Its findings connect AED pharmacology with steroidogenic mechanisms while also showing why in vitro inhibition must be separated from clinical causality and therapeutic exposure.

• Imipenem: Mechanism and Research Workflow

  2026-09-29

  Imipenem is a semisynthetic thienamycin antibiotic with broad activity against gram-negative and gram-positive bacteria. Its PBP-directed mechanism, immune response modulation findings, and defined sepsis animal model parameters support controlled antibacterial research while requiring careful interpretation outside those experimental conditions.

• BEND Lipids Improve mRNA and CRISPR Delivery

  2026-09-28

  The reference study introduces branched endosomal disruptor (BEND) ionizable lipids as a structural strategy for improving lipid nanoparticle delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complexes. Comparative delivery, gene-editing, T-cell transfection, and mechanistic experiments associate terminal branching with greater endosomal penetration and disruption, providing a framework for designing more effective nonviral carriers.

8570 records 1/572 page Next 12345 下5页 Last page